BioSpace News Archive

ZYUS Life Sciences Inc. announced today that its wholly owned U.S. subsidiary, ZYUS Life Sciences U.S. Ltd. has received one patent allowance notification and two patent issuances from the United States Patent and Trademark Office (USPTO).

Eisai Inc. announced today the presentation of findings from the company’s robust Alzheimer’s disease (AD) pipeline, including lecanemab (BAN2401).

Adagene Inc. today announced that it has entered into the clinical trial collaboration and supply agreement with Merck (known as “MSD” outside the United States and Canada), the leader among top immuno-oncology (IO) drugs on the market.

electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the second quarter ended June 30, 2021 after the close of the market on Thursday, August 5, 2021.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced that the Company is scheduled to release its second quarter 2021 financial results on Thursday, August 5, 2021, before the market opens.

Ocuphire Pharma, Inc. today announced the publication of a commentary article in the Journal of Cellular Signaling featuring its Ref-1 Inhibitor, APX3330, for the treatment of retinal disease.

VERO Biotech LLC today announced that they voluntarily issued a correction to Software version 2.2.3 for GENOSYL® DS devices, which is classified as a Class 1 recall.

Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology that enables antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announced the signature of a license and option agreement with ProfoundBio, an emerging oncology biotherapeutics company.

Inhalon Biopharma, Inc., a clinical-stage immunotherapy company developing an inhaled “muco-trapping” antibody platform for treating a variety of acute respiratory infections, today announced it is partnering with Celltrion, Inc. to develop IN-006, an inhaled form of regdanvimab, for treating patients with COVID-19.

Champions Oncology, Inc. today announced its financial results for the year and fourth fiscal quarter ended April 30, 2021.